[go: up one dir, main page]

SG10201913950XA - Liquid protein formulations containing viscosity-lowering agents - Google Patents

Liquid protein formulations containing viscosity-lowering agents

Info

Publication number
SG10201913950XA
SG10201913950XA SG10201913950XA SG10201913950XA SG10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA SG 10201913950X A SG10201913950X A SG 10201913950XA
Authority
SG
Singapore
Prior art keywords
formulations containing
lowering agents
protein formulations
liquid protein
containing viscosity
Prior art date
Application number
SG10201913950XA
Inventor
Alyssa Larson
Kevin Love
Alisha Weight
Alan Crane
Robert Langer
Alexander Klibanov
Original Assignee
Eagle Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Biologics Inc filed Critical Eagle Biologics Inc
Publication of SG10201913950XA publication Critical patent/SG10201913950XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61G—TRANSPORT, PERSONAL CONVEYANCES, OR ACCOMMODATION SPECIALLY ADAPTED FOR PATIENTS OR DISABLED PERSONS; OPERATING TABLES OR CHAIRS; CHAIRS FOR DENTISTRY; FUNERAL DEVICES
    • A61G3/00—Ambulance aspects of vehicles; Vehicles with special provisions for transporting patients or disabled persons, or their personal conveyances, e.g. for facilitating access of, or for loading, wheelchairs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
SG10201913950XA 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents SG10201913950XA (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361876621P 2013-09-11 2013-09-11
US201461940227P 2014-02-14 2014-02-14
US201461943197P 2014-02-21 2014-02-21
US201461946436P 2014-02-28 2014-02-28
US201461988005P 2014-05-02 2014-05-02
US201462008050P 2014-06-05 2014-06-05
US201462026497P 2014-07-18 2014-07-18
US201462030521P 2014-07-29 2014-07-29

Publications (1)

Publication Number Publication Date
SG10201913950XA true SG10201913950XA (en) 2020-03-30

Family

ID=51626611

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11201601730TA SG11201601730TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG11201601728YA SG11201601728YA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG10201913952TA SG10201913952TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201913950XA SG10201913950XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG10201806539XA SG10201806539XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG10201809401XA SG10201809401XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SG11201601730TA SG11201601730TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents
SG11201601728YA SG11201601728YA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG10201913952TA SG10201913952TA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201806539XA SG10201806539XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing ionic liquids
SG10201809401XA SG10201809401XA (en) 2013-09-11 2014-09-11 Liquid protein formulations containing viscosity-lowering agents

Country Status (16)

Country Link
US (13) US9833513B2 (en)
EP (8) EP3043776B1 (en)
JP (12) JP6412575B2 (en)
KR (5) KR102289825B1 (en)
CN (7) CN111202711B (en)
AU (10) AU2014318691B2 (en)
CA (4) CA2923843C (en)
ES (5) ES2959451T3 (en)
HK (1) HK1226309A1 (en)
IL (5) IL312865B2 (en)
MX (6) MX386756B (en)
RU (2) RU2675824C2 (en)
SG (6) SG11201601730TA (en)
SI (4) SI3043772T1 (en)
WO (4) WO2015038818A2 (en)
ZA (5) ZA201601968B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703481A (en) 2010-03-12 2016-02-26 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
US9447189B2 (en) 2011-04-01 2016-09-20 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
US20140348719A1 (en) * 2013-03-14 2014-11-27 Bureau Veritas Pharmaceutical compound stabilizing filter compositions and methods of making and using same
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
HUE047699T2 (en) * 2013-12-17 2020-05-28 Hoffmann La Roche Methods of treating cancer using PD-1-axis antagonists and taxanes
CA2938884C (en) 2014-02-07 2024-02-13 eXIthera Pharmaceuticals Inc. Substituted azetidine compounds and their use as factor xia or kallikrein inhibitors
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US11471479B2 (en) 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
MA44391A (en) * 2015-06-08 2019-01-23 Debiopharm Int Sa COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATES AND ANTI-CD20 ANTIBODIES
WO2016205320A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
TW202440904A (en) * 2015-08-04 2024-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
PL3337502T3 (en) * 2015-08-19 2021-01-11 Astrazeneca Ab Stable anti-ifnar1 formulation
MA42706A (en) 2015-08-28 2021-04-14 Debiopharm Int Sa ANTIBODIES AND ASSAYS FOR DETECTION OF CD37
WO2017049205A2 (en) * 2015-09-18 2017-03-23 Amunix Operating Inc. Growth hormone formulation
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA3129181C (en) * 2015-10-23 2023-10-31 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CN108289951A (en) * 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 Anti- factor D antibody and conjugate
US20210206834A1 (en) * 2015-12-03 2021-07-08 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
CA3010329A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
CN105699555B (en) * 2016-03-24 2018-09-11 中国标准化研究院 A kind of method for preparing liquid chromatography of 1-ethoxy-2-hydroxy-4-propenyl benzene
WO2017189433A1 (en) * 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201809786TA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna monoclonal antibodies targeting il-6 and cd126
US10934568B2 (en) * 2016-06-07 2021-03-02 National Technology & Engineering Solutions Of Sandia, Llc Conversion of sugars to ionic liquids
KR102441221B1 (en) * 2016-08-18 2022-09-07 리제너론 파마슈티칼스 인코포레이티드 Assays to Determine the Self-Binding Ability of Proteins Using Concentration-Dependent Self-Interacting Nanoparticle Spectroscopy
US11274289B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274137B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US10463733B1 (en) 2016-10-04 2019-11-05 United States of America as represented by the Secetary of the Air Force Ultra-stable protein ionic liquids
US11382976B1 (en) 2016-10-04 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11274163B1 (en) 2016-10-04 2022-03-15 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
US11385201B1 (en) 2019-09-30 2022-07-12 United States Of America As Represented By The Secretary Of The Air Force Ultra-stable protein ionic liquids
WO2018081460A1 (en) * 2016-10-27 2018-05-03 Eisai R&D Management Co., Ltd. Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
EP3535297B1 (en) 2016-11-02 2022-08-10 Debiopharm International, S.A. Methods for improving anti-cd37 immunoconjugate therapy
US12370242B2 (en) * 2016-11-02 2025-07-29 Polaris Group Formulations of pegylated arginine deiminase
EP3582801A4 (en) * 2017-02-16 2020-12-23 Reform Biologics LLC ADDITIVE COMPOUNDS FOR PROTEIN PROCESSING
JOP20190204A1 (en) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
AU2018255955A1 (en) * 2017-04-18 2019-12-05 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
EP3615065A1 (en) * 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11202003754YA (en) 2017-05-16 2020-05-28 Bhamis Research Laboratory Pvt Ltd High concentration protein formulations with reduced viscosity
US20200148757A1 (en) * 2017-06-30 2020-05-14 Korea Advanced Institute Of Science And Technology Conjugate of vegf-grab protein and drug, and use thereof
CA3073286A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
CN111107873A (en) * 2017-09-05 2020-05-05 默沙东公司 Compounds for reducing the viscosity of biologicals
CN111601614A (en) * 2017-11-07 2020-08-28 阿尔法科制药有限责任公司 Methods of treating and preventing heart disease, cardiovascular disease, and related conditions and symptoms
CN111918644A (en) * 2017-11-17 2020-11-10 哈佛大学校长及研究员协会 Ionic liquids for internal delivery
CN108096185A (en) * 2017-12-20 2018-06-01 珠海冀百康生物科技有限公司 A kind of Insulin Aspart and preparation method thereof
KR20230018549A (en) * 2018-03-07 2023-02-07 코메라 라이프 사이언시스, 인코포레이티드 Excipient compounds for protein formulations
WO2019201904A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN108671229B (en) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
KR20210014684A (en) 2018-05-30 2021-02-09 데비오팜 인터네셔날 에스 에이 Anti-CD37 immunoconjugate dosage regimen
US11730698B2 (en) * 2018-07-19 2023-08-22 Celltrion Inc. Stable liquid pharmaceutical preparation
WO2020079236A1 (en) * 2018-10-19 2020-04-23 F. Hoffmann-La Roche Ag Microdosing
CN113316458B (en) 2018-11-07 2024-08-02 默沙东有限责任公司 Co-formulations of anti-LAG 3 antibodies and anti-PD-1 antibodies
JP7637618B2 (en) * 2018-11-21 2025-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Highly concentrated protein formulations
US11058770B1 (en) * 2019-01-24 2021-07-13 United States Of America As Represented By The Secretary Of The Air Force Ultrastable antibody ionic liquids
JOP20210229A1 (en) 2019-02-18 2023-01-30 Lilly Co Eli A therapeutic antibody formulation
WO2020219506A1 (en) * 2019-04-24 2020-10-29 Janssen Biotech, Inc. Antibody formulation
EP3771463A1 (en) 2019-07-29 2021-02-03 Ludwig-Maximilians-Universität München Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
US20220331430A1 (en) * 2019-09-17 2022-10-20 Merck Patent Gmbh Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
US11684594B2 (en) 2020-05-12 2023-06-27 President And Fellows Of Harvard College Antifungal prophylaxis for cornea
WO2022178279A1 (en) 2021-02-19 2022-08-25 Nova Thin Film Pharmaceuticals Llc Method and system for manufacturing oral soluble films, compositions of oral soluble films, oral soluble films made by thereby, and methods of use thereof
CA3187322A1 (en) * 2020-07-13 2022-01-20 Merck Patent Gmbh Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
KR20230098144A (en) * 2020-09-01 2023-07-03 아이투오 테라퓨틱스, 인코포레이티드 Ionic liquid formulations for treating diabetes
CN113249358B (en) * 2021-05-14 2022-10-14 天津大学 Method for regulating and controlling crystal form of lysozyme by using ionic liquid
JP2024527538A (en) * 2021-07-01 2024-07-25 アップカラ インコーポレイテッド Ultra-concentrated formulation of bioactive agents
US20240350366A1 (en) * 2021-08-25 2024-10-24 Guido Knobel Device for producing a pharmaceutical, dietary supplement or cosmetic
IL312672A (en) 2021-11-10 2024-07-01 I2O Therapeutics Inc Ionic liquid compositions
CN115350330B (en) * 2022-09-01 2023-10-20 北京化工大学 Application of a negatively charged small molecule-controlled surface in differential protein adhesion
AU2024237541A1 (en) 2023-03-13 2025-08-28 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190082A (en) 1877-04-24 Improvement in apparatus for cooling liquids
GB750373A (en) 1953-01-15 1956-06-13 Pfizer & Co C Improvements in or relating to injectable suspension of penicillin salts
DK128416B (en) 1964-08-13 1974-04-29 Ciba Geigy Ag Analogous process for the preparation of adrenocorticotropically active nonadecapeptide amides or acid addition salts or complex compounds thereof.
BE757195A (en) 1969-10-07 1971-03-16 Century Disposable Devices SYRINGE FOR INJECTING A FRESHLY PREPARED MIXTURE OF POWDER AND LIQUID
JPS5270014A (en) 1975-12-05 1977-06-10 Senju Pharma Co Stabilization of pyrido*3*22a*phenoxadine compounds
US4171698A (en) 1977-08-15 1979-10-23 Abbott Laboratories Prefilled two-compartment syringe
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
ATE124999T1 (en) 1985-03-15 1995-07-15 Antivirals Inc POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS.
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5001000A (en) 1988-09-26 1991-03-19 E. I. Du Pont De Nemours And Company Process for forming a composite structure of thermoplastic polymer and sheet molding compound
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
JPH03190823A (en) * 1989-12-21 1991-08-20 Snow Brand Milk Prod Co Ltd Erythropoietin hypodermic or intramuscular administration agent
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69419721T2 (en) 1993-01-12 2000-04-27 Biogen, Inc. RECOMBINANT ANTI-VLA4 ANTIBODY MOLECULES
US5334162A (en) 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (en) 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
DE4344824C1 (en) 1993-12-28 1995-08-31 Immuno Ag Highly concentrated immunoglobulin preparation and process for its preparation
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3524974B2 (en) * 1994-12-26 2004-05-10 ブラッコ インターナショナル ビーヴィ Prefilled syringe and package thereof
US5569193A (en) 1995-03-22 1996-10-29 Abbott Laboratories Syringe system accommodating separately storable prefilled containers for two constituents
US5779668A (en) 1995-03-29 1998-07-14 Abbott Laboratories Syringe barrel for lyophilization, reconstitution and administration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19617369A1 (en) 1996-04-30 1997-11-06 Immuno Ag Storage-stable fibrinogen preparations
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US5819998A (en) 1996-09-30 1998-10-13 Everything Kids Knapsack with simulated basketball court
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
US6065645A (en) 1997-04-01 2000-05-23 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US5819988A (en) 1997-04-01 1998-10-13 Sawhney; Ravi K. Double-barreled syringe with detachable locking mixing tip
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DK1029548T3 (en) 1997-10-15 2007-07-02 Asahi Kasei Pharma Corp Process for maintaining the quality of aqueous parenteral solutions of thrombomodulin during storage and transport
US6451617B1 (en) 1997-10-22 2002-09-17 Chugai Seiyaku Kabushiki Kaisha Method of screening TGF-β inhibitory substances
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
FR2794649B1 (en) 1999-06-11 2003-04-11 Solutions BIOMATERIAL BASED ON AN INSOLUBILIZED DEXTRAN DERIVATIVE AND A GROWTH FACTOR, METHOD FOR PREPARING SAME AND ITS APPLICATIONS
AUPQ132599A0 (en) 1999-07-01 1999-07-22 Commonwealth Scientific And Industrial Research Organisation Nasogastric enteral formulations
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
EP1072323B1 (en) 1999-07-29 2003-09-10 Wilhelm A. Keller Cartridge discharge device with actuator for dynamic mixers
BR0014486A (en) 1999-10-04 2002-09-17 Chiron Corp Pharmaceutical compositions containing stabilized liquid polypeptide
US6394314B1 (en) 1999-10-12 2002-05-28 Discus Dental Impressions, Inc. Double-barreled syringe with detachable locking mixing tip
US6443612B1 (en) 1999-12-02 2002-09-03 Wilhelm A. Keller Dynamic mixer
DE60139944D1 (en) 2000-10-12 2009-10-29 Genentech Inc LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20020156418A1 (en) 2000-11-30 2002-10-24 Gonnelli Robert R. Injection systems
PL218876B1 (en) 2000-12-01 2015-02-27 Europaisches Lab Für Molekularbiologie Embl Rna interference mediating small rna molecules
AU2002257295B2 (en) 2001-05-16 2008-06-12 Biomarin Pharmaceutical Inc. Destruction of prions using vibriolysin or variants thereof
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
KR100895911B1 (en) 2001-08-02 2009-05-07 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Ceramic materials, abrasive grains, abrasive articles and methods of making and using them
JP4167820B2 (en) * 2001-10-19 2008-10-22 アルインコ株式会社 Deck plate traveling cart
GB0212405D0 (en) 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
KR20050038008A (en) * 2002-07-31 2005-04-25 알자 코포레이션 Injectable depot compositions and uses thereof
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
KR101363658B1 (en) 2003-03-05 2014-02-14 할로자임, 아이엔씨 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
AU2004227837A1 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
CN102258464A (en) 2003-04-04 2011-11-30 健泰科生物技术公司 High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US7341843B2 (en) 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
AU2004230482A1 (en) 2003-04-15 2004-10-28 Biozyme Laboratories, Ltd Process for isolating and purifing ovine hyaluronidase
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20070184084A1 (en) 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
EP2378288B1 (en) 2003-06-18 2015-09-09 The Scripps Research Institute Unnatural reactive amino acid genetic code additions
BRPI0411875A (en) 2003-06-23 2006-08-08 Sanofi Pasteur Inc immunization method against neisseria meningitidis serogroups a and c
CN1206344C (en) 2003-07-28 2005-06-15 中国海洋大学 Method for producing fucan sulfatase by means of bacteria
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1670500A2 (en) 2003-09-17 2006-06-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
GB0403938D0 (en) 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
ES2526194T3 (en) 2004-06-21 2015-01-08 E. R. Squibb & Sons, L.L.C. Interferon alfa 1 receptor antibodies, and their uses
EP1669414B1 (en) 2004-11-25 2010-05-26 Chr. Hansen A/S Method for the preparation of a carminic acid lake
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
PA8661401A1 (en) * 2005-01-28 2006-09-08 Wyeth Corp FORMULATIONS OF THE STABILIZED POLYPEPTIDE LIQUID
CN103271083B (en) 2005-10-07 2017-08-11 阿拉巴马大学 Multi-functional ionic liquid compositions
CN100416002C (en) * 2005-10-26 2008-09-03 曲新华 Sewage recycling apparatus
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
PL1962886T6 (en) 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stable protein formulations
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
JP5231810B2 (en) 2005-12-28 2013-07-10 中外製薬株式会社 Antibody-containing stabilized preparation
CN1823768A (en) 2006-01-09 2006-08-30 徐新盛 Cimetidine freeze dried composition
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
DE102006005094A1 (en) 2006-02-04 2007-08-09 Degussa Gmbh Titanium dioxide and polycarboxylate ether-containing dispersion
ITMI20061030A1 (en) 2006-05-26 2007-11-27 Altergon Sa NEW COMPOSITION INCLUDING GLYCOSAMINOGLICANS WITH CONTROLLED VISCOSITY AND USE OF SUCH COMPOSITION IN THE THERAPY OF CHRONIC CYSTITIS
CU23526B6 (en) 2006-10-03 2010-05-19 Ct Ingenieria Genetica Biotech METHOD FOR MORFOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY
WO2008092084A2 (en) 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
ES2660906T3 (en) 2007-05-31 2018-03-26 Anterios, Inc. Nucleic acid nanoparticles and uses thereof
CN102737949B (en) 2007-07-20 2016-09-07 应用材料公司 For the radio-frequency choke transmitted to the gas of RF driven electrode in plasma processing tool
WO2009015367A2 (en) 2007-07-25 2009-01-29 Arizona Board Of Regents For And On Behalf Of Arizona State University Stabilizing proteins using ionic liquids
JP2010536786A (en) 2007-08-17 2010-12-02 アムジエン・インコーポレーテツド Preparation of antibody and FC fusion molecule using polycation
WO2009043049A2 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
US8552046B2 (en) 2007-10-16 2013-10-08 Pharmacyclics, Inc. Manufacture, compositions and uses of coagulation factor VIIa modulator
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
CA2904458C (en) 2007-11-30 2017-07-25 Wolfgang Fraunhofer Protein formulations and methods of making same
EP2234636A4 (en) 2007-12-21 2013-05-15 Lyotropic Therapeutics Inc Stabilized formulations of peptides and proteins
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
US20120251615A1 (en) * 2008-01-18 2012-10-04 Horst Kief Agent for intra-articular injection
WO2009120684A1 (en) * 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009137471A2 (en) * 2008-05-05 2009-11-12 University Of Miami Azo dye related small molecule modulators of protein-protein interactions
EP2123307A1 (en) * 2008-05-20 2009-11-25 Hexal Ag Method for reducing leachables and extractables in syringes
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
TWI342781B (en) 2008-12-01 2011-06-01 Univ China Medical Blood sugar-modulating polypeptides
MX2011009306A (en) 2009-03-06 2011-10-13 Genentech Inc Antibody formulation.
WO2010129469A1 (en) * 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2010132047A1 (en) 2009-05-14 2010-11-18 Rensselaer Polytechnic Institute Guanosine/gmp gels and uses thereof
KR101882408B1 (en) 2009-05-20 2018-07-27 세키스이 메디칼 가부시키가이샤 Blood coagulation time prolonging agent
ES2758827T3 (en) 2009-06-17 2020-05-06 Biomarin Pharm Inc Lysosomal enzyme formulations
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010279569A1 (en) * 2009-08-04 2012-03-01 Genentech, Inc. Concentrated polypeptide formulations with reduced viscosity
AR078161A1 (en) * 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
EP2477603B1 (en) 2009-09-17 2016-03-30 Baxalta Incorporated Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
EP2491123B1 (en) 2009-10-20 2018-04-18 The Regents of The University of California Single molecule nucleic acid nanoparticles
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
PT3721904T (en) 2009-11-20 2021-11-15 Biocon Ltd Formulations of t1h antibody
WO2011069037A2 (en) 2009-12-03 2011-06-09 The University Of North Carolina At Charlotte Stabilization and storage of biological pharmaceutical compositions
CA2783351C (en) 2009-12-10 2021-09-07 Regents Of The University Of Minnesota Tal effector-mediated dna modification
EP2521528B1 (en) 2010-01-08 2014-08-20 Chanel Parfums Beauté Use of at least one extract of flowers of camellia japonica alba plena for moisturizing the skin
ES2716088T3 (en) 2010-02-04 2019-06-10 Csl Behring Ag Immunoglobulin preparation
RS61082B1 (en) 2010-02-26 2020-12-31 Novo Nordisk As Stable antibody containing compositions
EP2542221A4 (en) * 2010-03-01 2013-10-23 Cytodyn Inc PROTEIN CONCENTRATED FORMULATIONS AND USES THEREOF
US20130171128A1 (en) 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
JP2013522313A (en) 2010-03-17 2013-06-13 アボツト・リサーチ・ベー・フエー Anti-nerve growth factor (NGF) antibody composition
US20130028920A1 (en) * 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
CN101851267A (en) 2010-04-22 2010-10-06 江南大学 A kind of antibody protective agent and its application
EP2566510A1 (en) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Compositions and methods useful for reducing the viscosity of protein-containing formulations
SMT202000095T1 (en) * 2010-05-14 2020-03-13 Amgen Inc High concentration anti-sclerostin antibody formulations
GB201012179D0 (en) 2010-07-20 2010-09-01 Future Injection Technologies Injection device
JP5919606B2 (en) * 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド Improved high concentration anti-TNF alpha antibody liquid formulation
US8936827B2 (en) 2011-02-25 2015-01-20 Abbott Cardiovascular Systems Inc. Methods of loading a hollow stent with a drug or drug formulation
CN103582724A (en) 2011-04-07 2014-02-12 葛兰素史密斯克莱有限责任公司 Formulations with reduced viscosity
EP3058952A1 (en) 2011-04-07 2016-08-24 Glaxosmithkline LLC Formulations with reduced viscosity
WO2012155035A1 (en) 2011-05-12 2012-11-15 Medrad, Inc. Fluid injection system having various systems for controlling an injection procedure
RU2485133C2 (en) 2011-05-30 2013-06-20 Закрытое Акционерное Общество "Фарм-Синтез" Protein-polypeptide complex possessing tissue-specific regenerative-reparative and rejuvenating action on skin tissue, method for preparing it, and pharmaceutical composition thereof
CN102349895B (en) 2011-09-28 2013-04-10 海南良方医药有限公司 Cimetidine composition for injection and preparation method thereof
WO2013063280A1 (en) 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9364542B2 (en) * 2011-10-28 2016-06-14 Excelse Bio, Inc. Protein formulations containing amino acids
WO2013096835A1 (en) * 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
AU2013211824B2 (en) * 2012-01-27 2017-06-01 Gliknik Inc. Fusion proteins comprising IgG2 hinge domains
CN104271122A (en) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 Anti-vla1 (cd49a) antibody pharmaceutical compositions
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
ES3025360T3 (en) 2012-05-18 2025-06-09 Genentech Inc High-concentration monoclonal antibody formulations
EP4043564A1 (en) 2012-05-25 2022-08-17 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
KR20150024301A (en) 2012-05-25 2015-03-06 노파르티스 아게 Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
BR112014031841A2 (en) 2012-06-21 2017-06-27 Ucb Pharma Sa pharmaceutical formulation
KR20230065381A (en) 2012-07-25 2023-05-11 더 브로드 인스티튜트, 인코퍼레이티드 Inducible dna binding proteins and genome perturbation tools and applications thereof
KR20150041626A (en) 2012-08-09 2015-04-16 로슈 글리카트 아게 Asgpr antibodies and uses thereof
FR2994390B1 (en) 2012-08-10 2014-08-15 Adocia METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
FR2995214B1 (en) 2012-09-10 2014-11-21 Adocia REDUCED VISCOSITY SOLUTION OF HIGH CONCENTRATION PROTEIN
WO2014160083A1 (en) 2013-03-13 2014-10-02 Applied Cardiovascular Solutions, Llc. Methods, compositions, and devices for the occlusion of cavities and passageways
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11471479B2 (en) * 2014-10-01 2022-10-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US10812184B1 (en) 2019-04-03 2020-10-20 Board Of Trustees Of The University Of Alabama, For And On Behalf Of The University Of Alabama In Huntsville Signal analysis systems and methods

Also Published As

Publication number Publication date
EP4403187A3 (en) 2025-01-08
CN110496099A (en) 2019-11-26
AU2020202240A1 (en) 2020-04-23
AU2014318637B2 (en) 2020-01-23
KR102772684B1 (en) 2025-02-27
US20180177876A1 (en) 2018-06-28
ZA201601968B (en) 2018-07-25
BR112016005309A8 (en) 2021-06-22
IL275388B2 (en) 2024-10-01
US10646571B2 (en) 2020-05-12
JP6941137B2 (en) 2021-09-29
AU2020202407A1 (en) 2020-05-07
HK1225979A1 (en) 2017-09-22
US20210038718A1 (en) 2021-02-11
US20210030877A1 (en) 2021-02-04
WO2015038811A2 (en) 2015-03-19
US10821183B2 (en) 2020-11-03
CN105722500B (en) 2019-08-30
MX382917B (en) 2025-03-13
MX2021005907A (en) 2021-06-23
EP3043776A1 (en) 2016-07-20
JP2019073563A (en) 2019-05-16
KR20240042200A (en) 2024-04-01
JP2016530319A (en) 2016-09-29
JP6768858B2 (en) 2020-10-14
JP6840797B2 (en) 2021-03-10
KR102435648B1 (en) 2022-08-25
AU2020202240B2 (en) 2023-02-09
JP6564512B2 (en) 2019-08-21
CN110559435B (en) 2023-10-20
JP6463581B2 (en) 2019-02-06
CA2923843A1 (en) 2015-03-19
US20240285766A1 (en) 2024-08-29
IL244430A0 (en) 2016-04-21
JP2016530321A (en) 2016-09-29
JP7214697B2 (en) 2023-01-30
EP3043772A1 (en) 2016-07-20
AU2023229619A1 (en) 2023-10-05
SI3043776T1 (en) 2024-03-29
WO2015038782A1 (en) 2015-03-19
MX2016003182A (en) 2017-03-31
IL312865B1 (en) 2025-02-01
JP6469113B2 (en) 2019-02-13
NZ756401A (en) 2021-05-28
RU2016113283A3 (en) 2018-07-27
AU2023251546A1 (en) 2023-11-16
IL244430B (en) 2020-06-30
US20210085792A1 (en) 2021-03-25
JP6515105B2 (en) 2019-05-15
JP2019056006A (en) 2019-04-11
US20180085463A1 (en) 2018-03-29
KR20160055243A (en) 2016-05-17
US11986526B2 (en) 2024-05-21
CA2923844A1 (en) 2015-03-19
CN105722501B (en) 2019-07-26
US20180177875A1 (en) 2018-06-28
CN110496099B (en) 2022-06-21
ES2959451T3 (en) 2024-02-26
HK1225980A1 (en) 2017-09-22
EP3808338A1 (en) 2021-04-21
AU2023200941A1 (en) 2023-03-30
IL312865B2 (en) 2025-06-01
EP3043775A2 (en) 2016-07-20
JP2018199735A (en) 2018-12-20
US9833513B2 (en) 2017-12-05
AU2014318696A1 (en) 2016-04-07
ZA202102906B (en) 2023-12-20
NZ717918A (en) 2021-05-28
AU2020202408B2 (en) 2023-09-21
IL318339A (en) 2025-03-01
ES2972527T3 (en) 2024-06-13
IL275388B1 (en) 2024-06-01
SG10201913952TA (en) 2020-03-30
KR102295633B1 (en) 2021-08-30
ES2837629T3 (en) 2021-07-01
AU2014318696B2 (en) 2020-01-23
SG11201601728YA (en) 2016-04-28
SG10201809401XA (en) 2018-11-29
CN105705139A (en) 2016-06-22
EP3043775B1 (en) 2020-11-04
CN111202711A (en) 2020-05-29
EP3043774B1 (en) 2020-11-04
JP6412575B2 (en) 2018-10-24
KR20160054009A (en) 2016-05-13
SI3043775T1 (en) 2021-01-29
WO2015038818A2 (en) 2015-03-19
EP3791862B1 (en) 2024-05-29
WO2015038777A1 (en) 2015-03-19
AU2014318725A1 (en) 2016-04-07
ES2841134T3 (en) 2021-07-07
EP3791862C0 (en) 2024-05-29
EP4272763A3 (en) 2024-02-14
AU2020202407B2 (en) 2023-07-13
US20180153997A1 (en) 2018-06-07
KR102651018B1 (en) 2024-03-27
MX2021012049A (en) 2021-11-03
KR102289825B1 (en) 2021-08-17
SI3043774T1 (en) 2021-01-29
CA2923859A1 (en) 2015-03-19
US20240181063A1 (en) 2024-06-06
BR112016005309A2 (en) 2017-08-01
US10849977B2 (en) 2020-12-01
AU2014318691A1 (en) 2016-04-07
ZA201801669B (en) 2021-07-28
IL312865A (en) 2024-07-01
IL244433B (en) 2020-07-30
JP7583455B2 (en) 2024-11-14
US20150071922A1 (en) 2015-03-12
ZA201802108B (en) 2022-04-28
RU2710542C2 (en) 2019-12-27
MX386756B (en) 2025-03-19
AU2014318691B2 (en) 2020-01-23
RU2016113385A (en) 2017-10-16
JP2016534141A (en) 2016-11-04
CA2924069C (en) 2021-11-02
RU2675824C2 (en) 2018-12-25
KR20220123552A (en) 2022-09-07
EP3043774A2 (en) 2016-07-20
IL244433A0 (en) 2016-04-21
RU2019140607A (en) 2020-05-29
US10179172B2 (en) 2019-01-15
ZA202303593B (en) 2025-10-29
US20150071920A1 (en) 2015-03-12
WO2015038818A3 (en) 2015-07-16
NZ717944A (en) 2021-06-25
JP2016530318A (en) 2016-09-29
JP6774484B2 (en) 2020-10-21
US10821184B2 (en) 2020-11-03
EP3043772B1 (en) 2023-07-19
MX2016003183A (en) 2016-11-14
JP2023021352A (en) 2023-02-10
HK1225982A1 (en) 2017-09-22
CN105722501A (en) 2016-06-29
KR20210110396A (en) 2021-09-07
US20150071925A1 (en) 2015-03-12
US20150071921A1 (en) 2015-03-12
CN105722500A (en) 2016-06-29
EP3043776B1 (en) 2024-01-03
US11819550B2 (en) 2023-11-21
SG11201601730TA (en) 2016-04-28
ES2980815T3 (en) 2024-10-03
SI3043772T1 (en) 2023-10-30
IL275388A (en) 2020-07-30
CN110559435A (en) 2019-12-13
CN105848636B (en) 2020-02-21
CN105848636A (en) 2016-08-10
US9913905B2 (en) 2018-03-13
HK1226309A1 (en) 2017-09-29
AU2020202408A1 (en) 2020-05-07
CA2924069A1 (en) 2015-03-19
RU2019140607A3 (en) 2022-04-18
MX2021012050A (en) 2021-11-03
JP2025010224A (en) 2025-01-20
JP2020203956A (en) 2020-12-24
SG10201806539XA (en) 2018-08-30
EP4272763A2 (en) 2023-11-08
CN105705139B (en) 2019-07-26
EP4403187A2 (en) 2024-07-24
JP2019142985A (en) 2019-08-29
JP2019178176A (en) 2019-10-17
EP3791862A1 (en) 2021-03-17
NZ756260A (en) 2021-06-25
US9925263B2 (en) 2018-03-27
MX2021012048A (en) 2021-11-03
AU2014318637A1 (en) 2016-04-07
AU2014318725B2 (en) 2020-01-23
CN111202711B (en) 2022-06-21
CA2923844C (en) 2022-07-26
RU2016113283A (en) 2017-10-17
HK1225981A1 (en) 2017-09-22
AU2014318725A2 (en) 2019-02-14
CA2923843C (en) 2022-07-12
CA2923859C (en) 2021-11-23
WO2015038811A3 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
IL275388A (en) Liquid protein formulations containing viscosity-lowering agents
EP3076241A4 (en) Ultraviolet-ray-curable liquid developer
SG11201604459SA (en) Liquid detergent
SG11201508564QA (en) Cleaning liquid composition
ZA201600238B (en) Stable liquid formulation of amg 416 (velcalcetide)
HUE039180T2 (en) Liquid detergent composition
ZA201507331B (en) Liquid cleaning composition
EP3041352B8 (en) Cleaning liquid
GB2532663B (en) Liquid mouthwash
IL241040A0 (en) Raceadotril liquid compositions
GB2523951B (en) Liquid detergent
SG11201506298YA (en) Liquid container
EP2830607A4 (en) Polyvinylpyrrolidone-containing acetaminophen liquid formulations
HK40101422A (en) Liquid protein formulations containing organophosphates
PL2865740T3 (en) Liquid scouring composition
HK40112817A (en) Liquid protein formulations containing viscosity-lowering agents
EP2997114A4 (en) Ionic liquid composition
EP3088959A4 (en) Liquid developer
GB201315537D0 (en) Liquid mixer